

**Hoepfer MM et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry**

*J Heart Lung Transplant. 2020 September 29; DOI:https://doi.org/10.1016/j.healun.2020.09.011*

**STUDY HIGHLIGHTS**

**Background:** IPAH is characterized by pre-capillary PH of unknown origin. There is considerable variability in the clinical presentation.

**Objective:** Cluster analysis of large patient cohort from the COMPERA registry to identify clinical phenotypes of adult patients with IPAH.

**Design:** Prospective registry analysis (Clinicaltrials.gov identifier NCT01347216). 841 treatment naïve IPAH patients.

Hierarchical agglomerative clustering analysis using baseline parameters of age, sex, DLCO, smoking status, and comorbidities/risk factors for left heart disease (obesity, hypertension, coronary heart disease, diabetes mellitus).

**Outcomes:** survival, treatment response (functional class, change in 6MWD and BNP/NT-proBNP).


**Three clusters were identified:**

**Cluster 1:** 106 (12.6%) patients, median age 45 years, 76% female, 31% with smoking history, no comorbidities, all with DLCO  $\geq$ 45% pred.

**Cluster 2:** 301 (35.8%) patients, median age 75 years, 98% female, 0% with smoking history, 94% with at least 1 comorbidity. 34% with DLCO <45% pred.

**Cluster 3:** 434 (51.6%) patients, median age 72 years, 72% male, 79% with smoking history (median: 33 pack years), 91% with at least 1 comorbidity. 53% with DLCO <45% pred.

**Factors differentiating Cluster 3 from Cluster 2: increased frequency of male sex, smoking history and DLCO <45% (cardiopulmonary phenotype)**



**Results:**

Cluster 1 had a better response to PAH treatment than the other clusters.

5 year survival was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (p < 0.001).

Adjusted for age, the survival differences between Clusters 1 and 3 and Clusters 2 and 3 remained significant

**Limitations**

- Enrollment/selection bias
- Incomplete datasets
- Variables of interest selected in advance, necessitating a degree of assumption.
- The number of variables considered in this cluster analysis was relatively low.

**Reviewer comments:**

Whilst IPAH phenotypes may differ in clinical presentation, response to therapy, and survival, **poor survival in cluster 2 and 3 may also reflect the impact of age and comorbidities, which are well established risk factors for poor survival in PAH.**

DesJardin et al., Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Arterial Hypertension Association Registry.  
*J Heart Lung Transplant. 2020 Sept;39(9):945-953.*

**STUDY HIGHLIGHTS**

**Question:** What is the relationship between age and hemodynamic and functional assessment in PAH?


**Design:** Retrospective analysis of PAH patients in the Pulmonary Hypertension Association Registry

**Inclusion:** 769 PAH patients age  $\geq 18$  were included. Patients with CTEPH, persistent PH of the newborn, and PH due to congenital heart disease were excluded.


**Outcomes:** Hemodynamic profile and functional risk assessment in different age groups

**Results:** Older patients had more CTD-PAH and less drug induced-PAH. Increased age was associated with reduced 6MWD and lower mPAP. Pulmonary arterial compliance (PAC), cardiac index, RV stroke work index, and % predicted 6MWD were unrelated to age. Relative to their PVR, older patients had lower PAC and worse RV performance.


**CENTRAL FIGURES**



**Figure 2** Changes in baseline right ventricular function by age. (a) Age and right ventricular stroke work index. (b) Age and cardiac index.



**Figure 3** Changes in baseline pulmonary artery and right atrial pressures by age. mPAP, mean pulmonary artery pressure; PADP, pulmonary artery diastolic pressure; PASP, pulmonary artery systolic pressure; RAP, right atrial pressure.



**Figure 4** Changes in 6-minute walk distance by age. (a) Age and absolute 6-minute walk distance. (b) Age and percent predicted 6-minute walk distance.

**REVIEWER'S COMMENTS**

- In tracing the relationship between pulmonary arterial compliance and age, it is unclear which parameter in pulmonary arterial compliance calculation accounted for lack of variation with age.
- Factors that affect the RV ability to condition to increased afterload need to be considered.
- Relationship between functional measures and age is confounded by factors other than PAH.

**Limitations:**

- Important data on patients' comorbid conditions and PAH therapy was not presented.

Yogeswaran A et al. Risk assessment in severe pulmonary hypertension due to interstitial lung disease.  
*J Heart Lung Transplant. 2020 Oct;39(10):1118-1125.*

**STUDY HIGHLIGHTS**

**Question:** What is the prognostic value of a truncated version of the European Society of Cardiology/European Respiratory Society (ESC/ERS) pulmonary hypertension (PH) risk stratification scheme in severe PH with interstitial lung disease (ILD)?

**Design:** Retrospective single center study

**Inclusion:** All ILD patients who were referred for invasive diagnostic workup of suspected severe PH

**Outcomes:** Transplant (Tx) free survival, stratified by risk grade

**Results:** 5-year Tx-free survival of low, intermediate and high-risk patients was 43%, 15%, 4% ( $P=0.01$ ) respectively.


**CENTRAL FIGURES**

**Table 1** Variables and Thresholds Included in the Risk Stratification Scheme Used in This Study (8 of 12 Parameters From the ESC/ERS Scheme<sup>2</sup>)

Risk stratification parameter	Low risk (Grade 1)	Intermediate risk (Grade 2)	High risk (Grade 3)
WHO functional class	I, II	III	IV
6MWD, m	>440	165–440	<165
BNP, ng/liter	<50	50–300	>300
RA area, cm <sup>2</sup>	<18	18–26	>26
Pericardial effusion	No	No or minimal	Yes
RA pressure, mm Hg	<8	8–14	>14
Cardiac index, liter/min/m <sup>2</sup>	≥2.5	2.0–2.4	<2.0
SvO <sub>2</sub> , %	>65	60–65	<60

Abbreviations: 6MWD, 6-minute walk distance; BNP, brain natriuretic peptide; ESC/ERS, European Society of Cardiology/European Respiratory Society; RA, right atrial; SvO<sub>2</sub>, mixed venous oxygen saturation; WHO, World Health Organization.

**Risk stratification scheme is clinically relevant for prediction of Tx-free survival in patients with severe PH due to ILD**



**REVIEWER'S COMMENTS**

- A major strength is the inclusion of all ILD patients (not just IPF, IIP)
- Mean ( $\pm$ SD) mPAP was 42 ( $\pm$ 8)
- Tx was an infrequent outcome (only 5%)
- DLCO was not associated with increased mortality in severe PH with ILD, hence outcomes may have been driven primarily by RV function
- Role of PAH specific therapies remains unclear

**Limitations:**

- Retrospective single center analysis
- Possibility of selection and enrollment bias